Is Egrifta (Tesamorelin) Legal in Arizona? How to Access It Legally

HealthRX.com

Egrifta is FDA-approved, but state rules are not covered here

1.28 mgEgrifta WR daily dose; not substitutable with Egrifta SVSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.4 mgEgrifta SV daily dose, given as a subcutaneous injection into the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgEgrifta WR daily dose; not substitutable with Egrifta SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6.5%HbA1c level reached by 5% of tesamorelin-treated patients by week 26, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 25%Patients with injection-site reactions in the first 26 weeks, versus 14% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Approval / Egrifta first approved November 10, 2010, application BLA 022505 [1]
  • Current products / Egrifta SV 2 mg vial, 1.4 mg daily; Egrifta WR 11.6 mg vial, 1.28 mg daily; not substitutable [2][3]
  • Approved use / excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
  • Not indicated for / weight loss; the label describes a weight-neutral effect [2]
  • Marketing status / listed as a prescription product in Drugs@FDA [1]
  • Compounding / FDA has made no category-based statement about compounding tesamorelin [4][5][6]
  • Sport / WADA prohibits it at all times [7]
  • Route / subcutaneous injection into the abdomen, once daily [2][3]

What the federal approval covers

Egrifta (tesamorelin acetate) was first approved on November 10, 2010, as application BLA 022505 [1]. Two formulations are currently labeled: Egrifta SV, a 2 mg vial given as 1.4 mg subcutaneously once daily into the abdomen, and Egrifta WR, an 11.6 mg vial given as 1.28 mg once daily. The labels state that the two are not substitutable [2][3].

The indication is limited to reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3]. The label adds that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue, that the drug is not indicated for weight loss management because its effect on weight is neutral, and that there are no data to support improved adherence to antiretroviral therapy [2].

Tesamorelin is a growth hormone-releasing factor analog, not growth hormone: it binds and stimulates GRF receptors on pituitary somatotroph cells so the pituitary releases more of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [2].

Compounded tesamorelin

Tesamorelin is already the active ingredient in an FDA-approved drug [2]. It does not appear on FDA's list of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026) [4], and it falls in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [5][6]. FDA has therefore made no category-based statement about compounding it.

The HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026, names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not among them [8][9]. A compounded drug is not FDA-approved, and FDA does not review its safety, effectiveness or quality before it is marketed [8][9].

Sport

WADA names tesamorelin in section S2.2.4 (growth hormone releasing factors) and prohibits it at all times, in and out of competition. It is on the 2026 List and remains on the 2027 List [7][10].

What the label flags

The label contraindicates tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3].

IGF-1 rises on treatment: among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23%. The label says to monitor IGF-1 and to consider discontinuing with persistent elevations, for example above 3 SDS, particularly if the response is not robust [2]. HbA1c of 6.5% or higher developed in 5% of tesamorelin-treated patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 [2]. Hypersensitivity reactions occurred in 4% of treated patients, and injection-site reactions in 25% versus 14% on placebo during the first 26 weeks [2].

The most common reactions, above 5%, were arthralgia, injection-site redness, injection-site itching, pain in an extremity, peripheral edema and myalgia. In the label's combined table, arthralgia was 13% versus 11% on placebo, peripheral edema 6% versus 2%, and myalgia 6% versus 2% [2].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. Which use does the article describe as the only approved use of Egrifta?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Questions worth asking

Choose the questions you want to keep

Is tesamorelin legal in Arizona?
Egrifta is an FDA-approved prescription drug, and Drugs@FDA lists it as a prescription product [1][2]. This page covers federal status and does not address Arizona state rules.
What is Egrifta approved to treat?
Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label states it is not indicated for weight loss management because its effect on weight is neutral [2][3].
Is compounded tesamorelin legal?
Tesamorelin is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounded peptides, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [8][9].
Does the label allow use in people without HIV lipodystrophy?
The approved indication is limited to HIV-infected adults with lipodystrophy, and the label says the drug is not indicated for weight loss management [2].
Is tesamorelin banned in sport?
Yes. WADA names tesamorelin in section S2.2.4 and prohibits it at all times, in and out of competition, on both the 2026 and 2027 Lists [7][10].
What is the dose of Egrifta SV and Egrifta WR?
Egrifta SV is 1.4 mg injected subcutaneously into the abdomen once daily. Egrifta WR is 1.28 mg once daily. The labels state the two formulations are not substitutable [2][3].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is it legal to buy peptides?

For tesamorelin, the answer follows from its FDA status. Egrifta is an FDA-approved prescription medicine, while a compounded drug is not FDA-approved, and FDA does not review its safety, effectiveness or quality before it is marketed. HHS's draft enforcement-discretion policy for compounded peptides names six peptides, and tesamorelin is not among them.

What is tesamorelin FDA approved for?

Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label states it is not indicated for weight loss management because its effect on weight is neutral.

Do you need a prescription for peptides?

Egrifta is a prescription product, and Drugs@FDA lists it as one. Whether other peptides need a prescription is not established.

Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. World Anti-Doping Agency.
  8. Official web page.
  9. Official web page.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Arizona? How to Access It Legally